ROSEMARY ONWUKA: Open Payments
NPI 1154826089 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,686 in 15 payments from 10 companies in 2025. Trend: 2023 $1,231 · 2024 $2,059 · 2025 $1,686
Food & beverage: $1,686
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $399 |
| Janssen Pharmaceuticals, Inc | 3 | $374 |
| ABBVIE INC. | 2 | $249 |
| Alkermes, Inc. | 1 | $123 |
| AstraZeneca Pharmaceuticals LP | 1 | $122 |
| ViiV Healthcare Company | 1 | $122 |
| Otsuka America Pharmaceutical, Inc. | 1 | $113 |
| E.R. Squibb & Sons, L.L.C. | 1 | $112 |
| Teva Pharmaceuticals USA, Inc. | 1 | $54 |
| Exact Sciences Corporation | 1 | $19 |
Products named: CAPLYTA, INVEGA SUSTENNA, VRAYLAR, LYBALVI, DATROWAY, APRETUDE, ABILIFY MAINTENA, COBENFY.
Industry payments across CA — which companies pay providers there.
